• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

改善高胆固醇血症患者低密度脂蛋白胆固醇控制的联合策略的疗效:一项随机临床试验。

Efficacy of a Combined Strategy to Improve Low-density Lipoprotein Cholesterol Control Among Patients With Hypercholesterolemia: A Randomized Clinical Trial.

作者信息

Párraga-Martínez Ignacio, Escobar-Rabadán Francisco, Rabanales-Sotos Joseba, Lago-Deibe Fernando, Téllez-Lapeira Juan M, Villena-Ferrer Alejandro, Blasco-Valle Mariano, Ferreras-Amez José M, Morena-Rayo Susana, Del Campo-Del Campo José M, Ayuso-Raya M Candelaria, Pérez-Pascual José J

机构信息

Centro de Salud de La Roda, Gerencia de Atención Integrada de Albacete, Servicio de Salud de Castilla-La Mancha, Facultad de Medicina de Albacete, Universidad de Castilla-La Mancha, Albacete, Spain.

Centro de Salud Zona IV, Servicio de Salud de Castilla-La Mancha, Albacete, Spain.

出版信息

Rev Esp Cardiol (Engl Ed). 2018 Jan;71(1):33-41. doi: 10.1016/j.rec.2017.05.029. Epub 2017 Jun 23.

DOI:10.1016/j.rec.2017.05.029
PMID:28652127
Abstract

INTRODUCTION AND OBJECTIVES

Several interventions can improve low-density lipoprotein cholesterol (LDL-C) control. Our main objective was to evaluate the efficacy of a combined intervention to improve LDL-C control in patients with hypercholesterolemia. The study also assessed the efficacy of the intervention in improving adherence (pharmacological, diet, and exercise).

METHODS

A multicenter, parallel group, randomized clinical trial (primary care) was conducted in 358 adults diagnosed with hypercholesterolemia, whether receiving prior drug therapy or not. We compared 178 participants who received the combined intervention (written material, self-completed registration cards, and messages to mobile telephones) with 178 controls. The main outcome variable was the proportion of participants with adequate LDL-C control (target levels of the European guidelines on dyslipidemia and cardiovascular risk) at 24 months.

RESULTS

At 24 months, the mean reduction in LDL-C was significantly higher in the intervention group (23.8mg/dL [95%CI, 17.5-30.1]) than in the control group (14.6mg/dL [95%CI, 8.9-20.4]; P=.034). The mean LDL-C decrease was 13.1%±28.6%. At 1 year, the proportion of participants with adequate control was significantly higher in the intervention group than in the control group (43.7% vs 30.1%; P=.011; RR, 1.46). Adherence was significantly higher in the intervention group, both to drug therapy (77.2% vs 64.1%; P=.029) and exercise (64.9% vs 35.8; P<.001), but not to diet.

CONCLUSIONS

The combined intervention significantly reduced LDL-C (by more than 13% at 2 years) and improved the degree of LDL-C control in patients with hypercholesterolemia at 1 year.

摘要

引言与目的

多种干预措施可改善低密度脂蛋白胆固醇(LDL-C)的控制情况。我们的主要目的是评估一种联合干预措施对改善高胆固醇血症患者LDL-C控制情况的疗效。该研究还评估了该干预措施在提高依从性(药物治疗、饮食和运动方面)的疗效。

方法

在358名诊断为高胆固醇血症的成年人中开展了一项多中心、平行组、随机临床试验(初级保健),这些患者无论之前是否接受过药物治疗。我们将178名接受联合干预(书面材料、自行填写的登记卡以及手机短信)的参与者与178名对照组进行了比较。主要结局变量是在24个月时LDL-C得到充分控制(血脂异常和心血管风险欧洲指南的目标水平)的参与者比例。

结果

在24个月时,干预组LDL-C的平均降低幅度(23.8mg/dL [95%CI,17.5 - 30.1])显著高于对照组(14.6mg/dL [95%CI,8.9 - 20.4];P = 0.034)。LDL-C的平均降低幅度为13.1%±28.6%。在1年时,干预组中控制良好的参与者比例显著高于对照组(43.7%对30.1%;P = 0.011;RR,1.46)。干预组在药物治疗(77.2%对64.1%;P = 0.029)和运动(64.9%对35.8;P < 0.001)方面的依从性显著更高,但在饮食方面并非如此。

结论

联合干预显著降低了LDL-C(2年时降低超过13%),并在1年时改善了高胆固醇血症患者LDL-C的控制程度。

相似文献

1
Efficacy of a Combined Strategy to Improve Low-density Lipoprotein Cholesterol Control Among Patients With Hypercholesterolemia: A Randomized Clinical Trial.改善高胆固醇血症患者低密度脂蛋白胆固醇控制的联合策略的疗效:一项随机临床试验。
Rev Esp Cardiol (Engl Ed). 2018 Jan;71(1):33-41. doi: 10.1016/j.rec.2017.05.029. Epub 2017 Jun 23.
2
Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.氟伐他汀缓释片(80毫克)单药及与依折麦布(10毫克)联合使用对原发性高胆固醇血症患者低密度脂蛋白胆固醇及炎症参数的影响:一项为期12周的多中心、随机、开放标签、平行组研究。
Clin Ther. 2008 Jan;30(1):84-97. doi: 10.1016/j.linthera.2008.01.013.
3
Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.他汀类药物不耐受患者中抗 PCSK9 单克隆抗体对低密度脂蛋白胆固醇水平的影响:GAUSS 随机试验。
JAMA. 2012 Dec 19;308(23):2497-506. doi: 10.1001/jama.2012.25790.
4
Long-term Effects of Plant Stanols on the Lipid Profile of Patients With Hypercholesterolemia. A Randomized Clinical Trial.植物甾醇对高胆固醇血症患者血脂水平的长期影响。一项随机临床试验。
Rev Esp Cardiol (Engl Ed). 2015 Aug;68(8):665-71. doi: 10.1016/j.rec.2014.07.035. Epub 2014 Dec 23.
5
AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).AMG 145,一种针对 PCSK9 的单克隆抗体,可帮助高危患者实现国家胆固醇教育计划成人治疗专家组 III 低密度脂蛋白胆固醇目标:来自 LAPLACE-TIMI 57 试验的分析(使用 PCSK9 单克隆抗体抑制联合他汀类药物治疗进行 LDL-C 评估 - 心肌梗死溶栓治疗 57)。
J Am Coll Cardiol. 2014 Feb 11;63(5):430-3. doi: 10.1016/j.jacc.2013.09.048. Epub 2013 Oct 23.
6
Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.瑞舒伐他汀10毫克/天与阿托伐他汀10毫克/天对高危成年人影响的12周多中心随机开放标签比较:一项探索性研究
Clin Ther. 2004 Nov;26(11):1821-33. doi: 10.1016/j.clinthera.2004.11.015.
7
A protocol to evaluate the efficacy, perceptions, and cost of a cholesterol packaging approach to improve medication adherence.一项评估胆固醇包装方法在提高药物依从性方面的疗效、认知度和成本的方案。
Contemp Clin Trials. 2014 Sep;39(1):106-12. doi: 10.1016/j.cct.2014.08.003. Epub 2014 Aug 10.
8
Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.匹伐他汀与阿托伐他汀的疗效和耐受性比较:一项针对韩国高胆固醇血症患者的为期8周的多中心、随机、开放标签、剂量滴定研究。
Clin Ther. 2007 Nov;29(11):2365-73. doi: 10.1016/j.clinthera.2007.11.002.
9
A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.一项为期52周的随机、开放标签、平行组比较研究,旨在观察匹伐他汀和阿托伐他汀对日本低密度脂蛋白胆固醇水平升高且伴有糖耐量异常患者的高密度脂蛋白胆固醇水平及糖代谢的耐受性和影响。
Clin Ther. 2008 Jun;30(6):1089-101. doi: 10.1016/j.clinthera.2008.05.017.
10
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.依洛尤单抗或依折麦布联合中等强度或高强度他汀类药物治疗对高胆固醇血症患者 LDL-C 降低的影响:LAPLACE-2 随机临床试验。
JAMA. 2014 May 14;311(18):1870-82. doi: 10.1001/jama.2014.4030.

引用本文的文献

1
Effectiveness of patient-oriented intervention in primary prevention of cardiovascular diseases with statins: Open-label randomized study.以患者为导向的他汀类药物在心血管疾病一级预防中的干预效果:开放标签随机研究。
Caspian J Intern Med. 2025 Jun 23;16(3):458-467. doi: 10.22088/cjim.16.3.458. eCollection 2025 Summer.
2
A systematic review and meta-analysis testing the effect of lifestyle modification and medication optimization programs on cholesterol and blood pressure in patients with cardiovascular disease.一项系统性综述和荟萃分析,检验生活方式改变和药物优化方案对心血管疾病患者胆固醇和血压的影响。
Syst Rev. 2025 Jul 28;14(1):153. doi: 10.1186/s13643-025-02857-5.
3
Interventions to improve adherence to lipid-lowering drugs: a systematic review and meta-analysis.
改善降脂药物依从性的干预措施:一项系统评价和荟萃分析。
EClinicalMedicine. 2025 May 26;84:103270. doi: 10.1016/j.eclinm.2025.103270. eCollection 2025 Jun.
4
Comparative analysis of metabolic risk factors for progression of non-alcoholic fatty liver disease.非酒精性脂肪性肝病进展的代谢危险因素的比较分析
Clin Exp Hepatol. 2021 Jun;7(2):241-247. doi: 10.5114/ceh.2021.107567. Epub 2021 Jun 30.
5
Implementation strategies to improve statin utilization in individuals with hypercholesterolemia: a systematic review and meta-analysis.提高高胆固醇血症患者他汀类药物利用率的实施策略:系统评价和荟萃分析。
Implement Sci. 2021 Apr 13;16(1):40. doi: 10.1186/s13012-021-01108-0.
6
Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.基于手机的干预措施,用于提高成年人预防心血管疾病初级预防药物的依从性。
Cochrane Database Syst Rev. 2021 Mar 26;3(3):CD012675. doi: 10.1002/14651858.CD012675.pub3.
7
Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.基于手机的干预措施,用于提高成年人心血管疾病一级预防中所开药物的依从性。
Cochrane Database Syst Rev. 2018 Jun 22;6(6):CD012675. doi: 10.1002/14651858.CD012675.pub2.